Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Tax Provisions (2021 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Tax Provisions for 6 consecutive years, with $29000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions fell 71.84% year-over-year to $29000.0, compared with a TTM value of $21.3 million through Dec 2025, up 3256.13%, and an annual FY2025 reading of $21.4 million, up 874.09% over the prior year.
  • Tax Provisions was $29000.0 for Q4 2025 at Arrowhead Pharmaceuticals, down from $20.0 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $20.0 million in Q3 2025 and bottomed at -$3.3 million in Q4 2023.
  • Average Tax Provisions over 4 years is $2.3 million, with a median of $533000.0 recorded in 2024.
  • The sharpest move saw Tax Provisions plummeted 73.68% in 2024, then soared 3652.35% in 2025.
  • Year by year, Tax Provisions stood at $3.8 million in 2022, then tumbled by 187.53% to -$3.3 million in 2023, then skyrocketed by 103.11% to $103000.0 in 2024, then crashed by 71.84% to $29000.0 in 2025.
  • Business Quant data shows Tax Provisions for ARWR at $29000.0 in Q4 2025, $20.0 million in Q3 2025, and -$437000.0 in Q2 2025.